1 Lin L F, Doherty D H, Lile J D, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993, 260: 1130-1132？？
[2]
2 Kordower J H , Emborg M E, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science, 2000, 290: 767-773？？
[3]
3 Gill S S, Patel N K, Hotton G R, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med, 2003, 9: 589-595？？
[4]
4 Svendsen C N, Clarke D J, Rosser A E, et al. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol, 1996, 137: 376-388？？
[5]
5 Carpenter M K, Cui X, Hu Z Y, et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol, 1999, 158: 265-278？？
[6]
6 Svendsen C N, CaldwellL M A, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson’s disease. Exp Neurol, 1997, 148: 135-146？？
[7]
7 Klein S M, Behrstock S, McHugh J, et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res, 2002, 69: 955-965？？
[8]
8 Klein S M, Behrstock S, McHugh J, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther, 2005, 16: 509-521？？
[9]
9 Behrstock S, Ebert A, McHugh J, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to Parkinsonian rodents and aged primates. Gene Ther, 2006, 13: 379-388？？
[10]
10 Georgievska B, Kirik D, Bjorklund A, et al. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol, 2002, 177: 461-474？？
[11]
11 Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science, 1995, 268: 1766-1769？？
[12]
12 Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA, 1992, 89: 5547-5551？？
[13]
13 Koponen J K, Kankkonen H, Kannasto J, et al. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther, 2003, 10: 459-466？？
[14]
14 Zhou B Y, Ye Z H, Gao P, et al. Inducible and reversible transgene expression in human stem cells stably transduced by novel lentiviral vectors. Stem Cells, 2006, 779-789
[15]
15 Kirik D, Georgievska B, Bjorklund A, et al. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci, 2004, 7: 105-110？？
[16]
16 Judith F M, Josh R F, Wolfram K H, et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA, 1994, 91: 4509-4513？？
[17]
17 Deuschle U, Meyer W K, Thiesen H J. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol, 1995, 15: 1907-1914
[18]
18 Moosmann P, Georgiev O, Thiesen H J, et al. Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Krüppel-type zinc finger factor. Biol Chem, 1997, 378: 669-678
[19]
19 Mark A K, Joseph C G, Luigi N. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med, 2001, 7: 33-40？？
